Evidence map›Paper›PMID 32839220›Full record

ArticleAntimicrobial agents and chemotherapy2020

Evaluation of the Combination of Azithromycin and Naphthoquine in Animal Malaria Models.

Zhu-Chun Bei, Guo-Fu Li, Jing-Hua Zhao, Min Zhang, Xiao-Guang Ji, Jing-Yan Wang

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Microbiology spectrum · 2024
    Article
  3. Article
  4. Article
  5. Inhibitory Compounds Targeting Plasmodium falciparum Gyrase B.Antimicrobial agents and chemotherapy · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zhu-Chun BeiState Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China beizhuchun@hotmail.com jing-yan.wang@qq.com.ORCID 0000-0002-5089-989X
Guo-Fu LiState Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Jing-Hua ZhaoState Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Min ZhangState Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Xiao-Guang JiState Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Jing-Yan WangState Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China beizhuchun@hotmail.com jing-yan.wang@qq.com.
Institute of Microbiology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combination therapy using drugs with different mechanisms of action is the current state of the art in antimalarial treatment. However, except for artemisinin-based combination therapies, only a few other combinations are now available. Increasing concern regarding the emergence and spread of artemisinin resistance in

Indexed as

AntimalarialsMalariaMalaria, Falciparum1-NaphthylamineAminoquinolinesAnimalsAzithromycinDrug Therapy, CombinationMice1-NaphthylamineAminoquinolinesAntimalarialsAzithromycinnaphthoquineazithromycinchemotherapycombination therapymalarianaphthoquineprophylaxis

Identifiers

PMID32839220
PMCPMC7577135
OpenAlexW3080228942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.